In this model, we used ex vivo cultured Panc02-claudin 18.2 cells after one in vivo tumor passage, which contained approximately 90% CLDN18+ cells with the remaining CLDN18-negative cells, enabling us to explore any endogenous immunity induced by treatment (Figure S3A). This evidence concerns the gene CLDN18 and neoplasm.